COVID-19 patient care experience in the United Kingdom

Česká verzia

Authors: Bashar Aldhoon
Authors place of work: Oddělení kardiologie, Worcestershire Acute Hospitals NHS Trust, Worcester, Spojené království
Published in the journal: Vnitř Lék 2021; 67(E-3): 35-40
Category:

Summary

In response to the COVID-19 pandemic many health care systems have attempted to reorganize healthcare workforce. Many doctors and nurses have been redeployed to acute care wards. In order to ensure the best quality of care it is essential for health professionals to stay updated on clinical studies and novel therapeutical approaches. Most patients with COVID-19 who become seriously unwell have an acute respiratory illness and about 14 % will require non-invasive respiratory support. This article aims at presenting some of the approaches in respiratory support and drug therapy. The overview of management is based on current guidelines and conclusions of several studies. The author is aware of the fact that the approach in COVID-19 management may change over time based on the current state of knowledge. It is worth mentioning that regardless its severity clinical symptoms associated with COVID-19 pneumonia may only be minor and thus regular monitoring on standard wards is required. The article refers to recent studies related to dexamethasone and remdesivir. The treatment with interleukin-6 receptor antagonists is also discussed. Finally, other drugs in treatment of COVID-19 patients are mentioned.

Keywords:

COVID-19 – dexamethasone – non-invasive ventilation – oxygenotherapy – remdesivir – tocilizumab.

Zdroje

1. Shah S, Majmudar K, Stein A et al. Novel use of home pulse oximetry monitoring in COVID-19 patients discharged from the emergency department identifies need for hospitalization. Acad Emerg Med 2020; 27(8): 681-692. Dostupné z https://www.ncbi.nlm.nih. gov/pmc/articles/PMC7323027/pdf/ACEM-9999-na.pdf

2. Torjesen I. Covid-19: Patients to use pulse oximetry at home to spot deterioration. BMJ 2020; 371: m4151. Dostupné z https://www.bmj.com/content/bmj/371/bmj.m4151.full.pdf

3. Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA 2020; 323(15): 1499-1500. Dostupné z https://jamanetwork.com/journals/jama/fullarticle/ 2762996.

4. Guan WJ, Ni ZY, Hu Y et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720. Dostupné z https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092819/pdf/NEJMoa2002032.pdf.

5. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA 2020; 323(22): 2329-2330. Dostupné z https://jamanetwork.com/journals/jama/fullarticle/2765302.

6. Archer SL, Sharp WW, Weir EK. Differentiating COVID-19 pneumonia from acute respiratory distress syndrome (ARDS) and high altitude pulmonary edema (HAPE): therapeutic implications. Circulation 2020; 142: 101–104. Dostupné z https://www.ahajournals.org/ doi/epub/10.1161/CIRCULATIONAHA.120.047915.

7. Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383(2): 120–128. Dostupné z https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC7412750/pdf/nihms-1610775.pdf.

8. Nightingale R, Nwosu N, Kutubudin F et al. Is continuous positive airway pressure (CPAP) a new standard of care for type 1 respiratory failure in COVID-19 patients? A retrospective observational study of a dedicated COVID-19 CPAP service. BMJ Open Respir Res 2020; 7(1): e000639. Dostupné z https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337881/pdf/ bmjresp-2020-000639.pdf.

9. Oranger M, Gonzalez-Bermejo J, Dacosta-Noble P et al. Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective ca se-control study. Eur Respir J 2020; 56(2): 2001692. Dostupné z https://www.ncbi.nlm.nih. gov/pmc/articles/PMC7241113/pdf/ERJ-01692-2020.pdf.

10. Grieco DL, Menga LS, Cesarano M et al. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure The HENIVOT Randomized Clinical Trial. JAMA. doi:10.1001/jama.2021.4682 Published online March 25, 2021.

11. Bamford P, Bentley A, Dean J et al. ICS guidance for prone positioning of the conscious COVID patient 2020. Intensive Care Society, 2020. Dostupné z https://emcrit.org/wp-content/ uploads/2020/04/2020-04-12-Guidance-for-conscious-proning.pdf.

12. Helms J, Tacquard C, Severac F et al. CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46: 1089-1098. Dostupné z https://www.ncbi.nlm. nih.gov/pmc/articles/PMC7197634/pdf/134_2020_Article_6062.pdf.

13. Pellicori P, Doolub G, Wong CM et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database of Systematic Reviews 2021; Issue 3. Art. No.: CD013879. Dostupné z https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858. CD013879/epdf/full.

14. Malbrain MLNG, Ho S, Wong A. Thoughts on COVID-19 from the International Fluid Academy. ICU Management & Practice 2020; 1: 80–85. Dostupné z https://healthmanagement. org/uploads/article_attachment/icu1-v20-thoughtsoncovid-19.pdf.

15. RECOVERY Collaborative Group: Horby P, Lim WS, Emberson JR et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384(8): 693–704. Dostupné z https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383595/pdf/NEJMoa2021436.pdf

16. Vimaleswaran KS, Forouhi NG, Khunti K. Vitamin D and covid-19. BMJ 2021; 372: n544. Dostupné z https://www.bmj.com/content/bmj/372/bmj.n544.full.pdf.

17. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 – Final Report. N Engl J Med 2020; 383: 1813-1826. Dostupné z https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC7262788/pdf/NEJMoa2007764.pdf.

18. Mehta RM, Bansal S, Bysani S et al. A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: a real- world analysis. Int J Infect Dis 2021; PII: S1201-9712(21)00178-8. Dostupné z https://www. sciencedirect.com/science/article/pii/S1201971221001788.

19. REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 2021 Feb 25:NEJMoa2100433. doi: 10.1056/NEJMoa2100433. Dostupné z https://www.nejm.org/doi/full/10.1056/NEJMoa2100433.

20. RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021; preprint. Dostupné z https:// www.medrxiv.org/content/10.1101/2021.02.11.21249258v1.

21. Chen P, Nirula A, Heller B et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 2021; 384: 229–237. Dostupné z https://www.ncbi. nlm.nih.gov/pmc/articles/PMC7646625/pdf/NEJMoa2029849.pdf.